
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
​Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.
Daniel Hamstra, MD, PhD, physician, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer. Hamstra says on average, patients come in to receive radiotherapy for about two months, five days per week, on average. With shorter, equally efficacious doses of radiotherapy, these patients can continue on with their day-to-day lives less impeded by their treatment.






